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The biosynthesis and secretion of human interleukin-6 (IL-6) was studied in monocyte cultures stimulated with endotoxin. 
After labeling with P%]methionine and immunoprecipitation with a specific antiserum one major (24 kDa) and four 
minor (27.5, 23.3, 22.5 and 21.8 kDa) molecular mass forms of IL-6 could be found in the cells and media. Incubation 
of monocyte media with sialidase and subsequently with endo-a-N-acetylgalactosaminidase, which cleaves Gal(Bl-3)Gal- 
NAc from serine or threonine, led to the formation of only two forms of IL-6 with apparent molecular masses of 25 
and 21.8 kDa. The latter had an electrophoretic mobility indistinguishable from that of ‘ZSI-labeled recombinant human 
IL-6. The results suggest that human monocyte IL-6 carries O-glycosidically bound carbohydrates with a Gal(Bl-3)Gal- 
NAc core to which only sialic acid is bound. Differences in O-glycosylation are the major cause for the molecular hetero- 
geneity of IL-6. A small part of IL-6 (27.5 kDa form) is in addition N-glycosylated. Incubation of monocytes with tunica- 
mycin and I-deoxymynnojirimycin and treatment of IL-6 with endoglucosaminidase H suggested that the 27.5 kDa form 
of IL-6 carries at least one N-linked complex-type oligosaccharide chain. 
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1. INTRODUCTION 
IL-6 is a cytokine produced by various cell types, 
among others, monocytes, macrophages, fibro- 
blasts and endothelial cells. Its synthesis can be in- 
duced by different stimuli, e.g. IL-l, TNF-(Y, 
PDGF and different viruses and bacterial products 
such as endotoxon [l-7]. IL-6 exerts a multitude of 
biological activities in the network of cytokines 
that is important in the regulation of the 
hematopoetic and immune systems (for a recent 
review see [8]). IL-6 is the major stimulus for the 
induction of acute-phase protein synthesis in the 
liver [9-l 11. 
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Multiple forms of IL-6 have been described with 
molecular masses ranging between 20 and 30 kDa 
[12-161. Mayet al. [14] found at least five forms of 
IL-6 in human fibroblasts. They demonstrated that 
IL-6 is both 0- and N-glycosylated and in addition 
phosphorylated [ 151. Similarly, Bauer et al. [ 161 
described five molecular mass forms of IL-6 in 
human monocytes and confirmed the existence of 
N-glycosylated forms. Absence or presence of N- 
glycosylation, however, can only account for two 
different molecular mass forms of IL-6 and does 
not explain the observed molecular heterogeneity. 
We therefore analyzed the O-linked carbohydrate 
side chains of human monocyte IL-6 by digestion 
with sialidase and endo-cu-N-acetylgalactos- 
aminidase and found that differences in O-linked 
carbohydrate side chains are the major cause for 
the molecular heterogeneity of IL-6. 
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2. MATERIALS AND METHODS 3. RESULTS AND DISCUSSION 
2.1. Materials 
L-[‘%]methionine (> 1000 CVmmol) was purchased from 
Amersham-Buchler (Braunschweig, FRG). Ficoll-paque and 
protein A-Sepharose were from Pharmacia (Freiburg, FRG). 
I-Deoxymannojirimycin, endoglucosaminidase H from Strep- 
tomyces plicatus and endo+-N-acetylgalactosaminidase w re 
from Boehringer (Mannheim, FRG). Sialidase from Vibrio 
cholerae was from Calbiochem (Giessen, FRG), tunicamycin 
from Sigma (Munchen, FRG). 
2.2. Preparation of an antiserum against human IL-6 
A specific antiserum against human IL-6 was obtained in a 
rabbit by two successive subcutaneous injections of 100 pg of 
recombinant human IL-6 in Freund’s complete adjuvant at a 
three week interval followed by a third injection four weeks later 
with 50 pg of IL-6 in Freund’s incomplete adjuvant. The anti- 
serum impaired the biological activity of IL-6 measured by the 
induction of fibrinogen mRNA in Fao cells [lo]. 
2.3. Iodination of recombinant human IL-6 
Iodination of recombinant human IL-6 was carried out as 
described [17]. 
2.4. Human monocyte cultures, radioactive labeling, 
immunoprecipitation a d electrophoresis 
Human monocytes were prepared from buffy coats as 
described by Andreesen et al. [18]. Mononuclear cells were 
separated from granulocytes and residual erythrocytes by cen- 
trifugation over Ficoll-paque. Monocytes were then separated 
from lymphocytes by adherence to plastic at 37°C in RPM1 1640 
medium containing 10% fetal calf serum. The adherent cells 
were then incubated overnight with RPM1 1640 medium con- 
taining 5% fetal calf serum at 37°C in a humidified atmosphere 
containing 5% COz. Monocytes (about 2 x lo6 cells/dish) ob- 
tained after overnight incubation were radioactively labeled 
with [“Slmethionine (150 &i/dish) for 3 h. When monocytes 
were incubated with tunicamycin (5 pug/ml) or l-deoxy- 
mannojirimycin (4 mM), the respective drugs were added to the 
cells 1 h prior to the radioactive labeling and were kept in the 
cell media at the same concentrations during the labeling period. 
At the end of the incubation the media were separated from the 
cells. IL-6 was immunoprecipitated from cells and media as 
described [19]. The immunoprecipitated IL-6 was analyzed by 
SDS-polyacrylamide gel electrophoresis 1201 and fluorography 
WI. 
Human monocyte cultures (2 x lo6 cells) were 
labeled with [35S]methionine for 3 h to study the 
biosynthesis and secretion of IL-6. In monocyte 
cultures stimulated with endotoxin (100 ng/ml 
medium) different molecular mass forms of IL-6 
could be found in cells and media.(fig. 1). Since the 
most of newly synthesized IL-6 had been secreted 
during the labeling period only faint bands which 
had the same electrophoretic mobilities as secreted 
IL-6 (fig. 1, lanes 4,7) could be found in the cells 
(fig.1, lanes 3,5). The predominant form of human 
IL-6 had an apparent molecular mass of 24 kDa. 
This is in accordance with the findings of May et al. 
[14,15] and Bauer et al. [16]. Besides this 24 kDa 
form a higher molecular mass form (27.5 kDa) and 
three low molecular mass forms (21.8 kDa, 
22.5 kDa and 23.3 kDa) could be detected. The 
21.8 kDa and 22.5 kDa forms were only faint 
bands. The synthesis of all these different 
molecular mass forms of IL-6 was less when mono- 
cytes were cultured in endotoxin-free media (fig. 1, 
lanes 1,2). 
2.5. Glycosidase treatment 
For sialidase treatment, monocyte media were dialyzed ex- 
haustively against 50 mM sodium acetate buffer, pH 5.5, 
1 .O mM CaClz and subsequently incubated with sialidase from 
Vibrio cholerae (200 mu/ml medium) at 37°C for 16 h. The 
sialidase-treated monocyte media were further dialyzed against 
20 mM sodium phosphate buffer, pH 6.5, and incubated with 
25 mU of endo-cu-N-acetylgalactosaminidase fromDiplococcus 
pneumoniae at 37’C for 16 h. 
To exclude the possibility that the different 
molecular mass forms of IL-6 were due to con- 
taminations appearing during immunoprecipita- 
tion competition experiments were carried out. 
When immunoprecipitations were done in the 
presence of 10 pg of unlabeled recombinant human 
IL-6 the intensity of all the bands representing IL-6 
(27.5, 24, 23.3, 22.5 and 21.8 kDa) was strongly 
decreased, while the intensity of some higher 
molecular mass contaminating bands (especially 
found in cells) remained unchanged (fig. 1, lanes 
6,8). The faint band (arrow) above the 27.5 kDa 
form of IL-6 was not strongly suppressed when the 
immunoprecipitation was carried out in the 
presence of unlabeled IL-6, suggesting that this 
band represents a contamination rather than a 
form of IL-6. 
For endoglucosaminidase H treatment, the ILd-IgG com- 
plexes eluted from protein A-Sepharose were dialyzed ex- 
haustively against 50 mM sodium phosphate buffer, pH 6.0, 
containing 0.01 mg/ml SDS and incubated in a total volume of 
0.1 ml with 5 mU of endoglucosaminidase H at 37°C for 16 h. 
Our pattern of human monocyte IL-6 obtained 
by SDS-polyacrylamide gel electrophoresis is 
similar, but not identical to that described by May 
et al. [14]. They found in fibroblasts a lower 
molecular mass doublet (23 and 25 kDa), and a 
higher molecular mass triplet (28, 29 and 30 kDa). 
When N-glycosylation of IL-6 was inhibited by 
incubation of monocytes with tunicamycin, the 
27.5 kDa form of IL-6 disappeared, whereas the 
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Fig. 1. Biosynthesis and secretion of IL-6 by human monocytes. 
Human monocyte cultures were incubated without (lanes 1,2) or 
with (lanes 3-8) 100 ng/ml of endotoxin for 16 h and subse- 
quently labeled with [“S]methionine (150 &i/Z. X lo6 cells) for 
3 h. IL-6 was immunoprecipitated from the cells (c) (lanes 
1,3,5,6) and media (m) (lanes 2,4,7,8) in either the absence 
(lanes l-5,7) or presence (lanes 6,s) of 10 fig of unlabeled re- 
combinant human IL-6. 
other molecular mass forms remained unchanged 
(fig.2, lanes 2,4). This indicates that only the 
27.5 kDa form of IL-6 is N-glycosylated. The N- 
glycosylated form of IL-6 could not be de- 
glycosylated by endoglucosaminidase H (fig.2, 
lanes 5,6). When monocytes were incubated with 
l-deoxymannojirimycin, which impairs the syn- 
thesis of complex-type oligosaccharides and leads 
to the accumulation of high mannose-type precur- 
sor oligosaccharides [22], the ZV-glycosylated form 
of IL-6 had a smaller apparent molecular mass and 
could be deglycosylated by endoglucosaminidase H 
(fig.2, lanes 7,8). This indicates that the 27.5 kDa 
form of IL-6 carries at least one N-asparagine 
bound complex-type carbohydrate side chain. 
Since we found only one N-glycosylated form of 
IL-6, there is obviously less heterogeneity in the N- 
glycosylated forms of IL-6 in our monocyte system 
than in the fibroblasts used by others, who ob- 
tained a triplet of N-glycosylated IL-6 bands [ 141. 
The primary structure of human IL-6 has two 
potential N-glycosylation sites [23]. Since incuba- 
tion of monocytes with low concentrations of 
tunicamycin and incomplete endoglucosaminidase 
H treatment of monocyte media treated with l-de- 
oxymannojirimycin did not yield an IL-6 of a 
cm cm mmm m t-a m m rat. 
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Fig.2. Deglycosylation of human IL-6. IL-6 was immuno- 
precipitated from the cells (lanes 1,3) or media (lanes 2,4) of un- 
treated (lanes 1,2) or tunicamycin-treated (lanes 3,4) monocyte 
cultures. To analyze N-linked carbohydrates IL-6 was immuno- 
precipitated from untreated (lanes 5,6) or l-deoxymannojiri- 
mycin-treated (lanes 7,8) monocyte cultures and incubated with- 
out (lanes 5,7) or with (lanes 6,8) endoglucosaminidase H. To 
analyze O-linked carbohydrates IL-6 was immunoprecipitated 
from untreated monocyte media (lane 9) or from media in- 
cubated with sialidase (lane 10) and from media incubated with 
sialidase and subsequently with endo-cu-N-acetylgalactos- 
aminidase (lane 11). For comparison, lane 12 shows ‘251-labeled 
recombinant human IL-6. 
molecular mass between 27.5 and 24 kDa (not 
shown), IL-6 apparently carries only one N-linked 
oligosaccharide chain. 
Incubation of monocyte media with sialidase led 
to increased electrophoretic mobilities of the 27.5, 
24 and 23.3 kDa forms of IL-6 (fig.2, lane 10). Ad- 
ditional incubation of the sialidase-treated mono- 
cyte media with endo-a-N-acetylgalactosamini- 
dase, which cleaves Gal(Jl-3)GalNAc from serine 
or threonine, led to the formation of only two 
forms of IL-6 with apparent molecular masses of 
25 kDa (cleavage product of the 27.5 kDa form) 
and 21.8 kDa (fig.2, lane 11). The electrophoretic 
mobility of the latter was indistinguishable from 
that of ‘251-labeled recombinant human IL-6 (fig.2, 
lane 12). 
The glycosidase digestion experiments clearly in- 
dicate that the molecular heterogeneity of human 
monocyte IL-6 is mainly due to differences in O- 
glycosylation. The results allow the conclusion that 
human IL-6 carries 0-glycosidically bound carbo- 
hydrates with a Gal(@l-3)GalNAc core to which 
only sialic acid is bound. The number of O-linked 
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carbohydrate side chains per IL-6 molecule and the 
exact binding site of sialic acid, however, remain to 
be determined. 
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